OLD National Bancorp IN Sells 564 Shares of Amgen Inc. (NASDAQ:AMGN)

OLD National Bancorp IN lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 7.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,793 shares of the medical research company’s stock after selling 564 shares during the period. OLD National Bancorp IN’s holdings in Amgen were worth $1,771,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Sanctuary Advisors LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $21,049,000. Newbridge Financial Services Group Inc. raised its position in shares of Amgen by 99.1% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 840 shares of the medical research company’s stock valued at $263,000 after acquiring an additional 418 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Amgen during the 2nd quarter valued at $16,515,000. Anchor Investment Management LLC raised its position in shares of Amgen by 3.1% during the 2nd quarter. Anchor Investment Management LLC now owns 6,211 shares of the medical research company’s stock valued at $1,941,000 after acquiring an additional 187 shares during the last quarter. Finally, Centaurus Financial Inc. raised its position in shares of Amgen by 16.8% during the 2nd quarter. Centaurus Financial Inc. now owns 1,615 shares of the medical research company’s stock valued at $505,000 after acquiring an additional 232 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.8 %

Shares of AMGN stock opened at $284.02 on Friday. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm’s 50-day moving average is $271.35 and its 200-day moving average is $304.99. The stock has a market cap of $152.67 billion, a price-to-earnings ratio of 36.37, a PEG ratio of 2.78 and a beta of 0.56. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.96 EPS. Sell-side analysts predict that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.35%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 115.24%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Barclays upped their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Bank of America restated an “underperform” rating and issued a $256.00 price objective on shares of Amgen in a research report on Tuesday, December 10th. Finally, Redburn Partners lowered their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.